Document Detail

Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis.
MedLine Citation:
PMID:  11438443     Owner:  NLM     Status:  MEDLINE    
Today, it is well established that besides playing a crucial role in the establishment and maintenance of the calcium homeostasis in the body, the active form of vitamin D, 1,25(OH)2D3, also acts an effective regulator of cell growth and differentiation in a number of different cell types, including cancer cells. This has led to an increased interest in using 1,25(OH)2D3 in the treatment or prevention of cancer patients and to a substantial number of studies investigating the effect of 1,25(OH)2D3 on cancer cells. The results are encouraging, but clearly demonstrate that the therapeutic window of 1,25(OH)2D3 is extremely narrow due to the calcemic adverse effects of this compound. Much effort has consequently been directed into identifying vitamin D analogs with potent cell regulatory effects but with weaker effects on the calcium metabolism than those of 1,25(OH)2D3. In an attempt to clarify the mechanisms implicated in the cell regulatory effects of 1,25(OH)2D3 and eventually facilitate the process of developing new specific vitamin D analogs, numerous investigations have been carried out with 1,25(OH)2D3 and its analogs. The present review will focus on the results obtained in these studies and describe some of the synthetic analogs, which have shown to be of particular interest in relation to cancer.
C M Hansen; L Binderup; K J Hamberg; C Carlberg
Related Documents :
18326613 - Plasma folate, vitamin b-6, vitamin b-12, and risk of breast cancer in women.
6088043 - Towards the dietary prevention of cancer: contributions of epidemiology.
15067103 - The correlation of microsatellite instability and tumor-infiltrating lymphocytes in her...
Publication Detail:
Type:  Journal Article; Review     Date:  2001-07-01
Journal Detail:
Title:  Frontiers in bioscience : a journal and virtual library     Volume:  6     ISSN:  1093-4715     ISO Abbreviation:  Front. Biosci.     Publication Date:  2001 Jul 
Date Detail:
Created Date:  2001-07-04     Completed Date:  2001-12-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9709506     Medline TA:  Front Biosci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  D820-48     Citation Subset:  IM    
Department of Biochemistry, University of Kuopio, P.O.B. 1627, FIN-70211 Kuopio, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects
Breast Neoplasms / metabolism
Calcitriol / analogs & derivatives*,  pharmacology
Cell Cycle / drug effects
Cell Differentiation / drug effects
Drug Resistance, Neoplasm
Growth Substances / metabolism
Neoplasm Invasiveness / prevention & control
Neoplasm Metastasis / physiopathology,  prevention & control
Neoplasms, Experimental / drug therapy*,  pathology,  physiopathology*
Prostatic Neoplasms / drug therapy,  physiopathology
Steroid Hydroxylases / metabolism,  pharmacology*
Telomerase / metabolism
Tumor Cells, Cultured
Reg. No./Substance:
0/Antineoplastic Agents; 0/Growth Substances; 103909-75-7/maxacalcitol; 134404-52-7/seocalcitol; 32222-06-3/Calcitriol; EC 1.14.-/Steroid Hydroxylases; EC 1.14.-/vitamin D 1-alpha hydroxylase; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  PKC in eggs and embryos.
Next Document:  Circulating breast cancer cells are frequently apoptotic.